Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy

Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy Publisher

Dehghanimahmoudabadi A¹ ; Kianfar N¹ ; Akhdar M¹ ; Dasdar S¹ ; Balighi K¹ ; Mahmoudi H¹ ; Daneshpazhooh M¹

Show Affiliations

1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: International Journal of Women's Dermatology Published:2022

Abstract

Background: Rituximab (RTX) is an effective treatment for pemphigus; however, the drug labeling recommends not to use RTX within 1 year before conception. Objectives: To report pregnancy outcomes of patients with pemphigus who were treated with RTX before or during pregnancy. Methods: We identified 19 pregnancies with RTX exposure before or during pregnancy. All had previously been advised not to get pregnant within 1 year of RTX administration. The cases were categorized into 3 groups of exposure of within 6 months (group A), between 6 and 12 months (group B), and longer than 12 months of conception (group C). The pregnancy outcomes of different RTX exposure intervals were compared. Results: Group A included 9 pregnancies, of which 3 had received RTX accidentally after conception. Group B and C included 4 and 6 pregnancies, respectively. There was no significant difference between the groups regarding pregnancy outcomes. Overall, there were 17 live births, 1 spontaneous abortion, and 1 termination. Of the live births, 3 preterm deliveries and 4 low-birth-weight neonates were noted. Moreover, 1 neonate was hospitalized due to early-onset neonatal sepsis, and 1 had hydronephrosis. Disease flare-up occurred in 5 patients during pregnancy (4 minor and 1 major relapses) and in 5 patients after delivery (3 minor and 2 major relapses). Conclusions: Except for 1 case of neonatal sepsis which survived following medical treatment, no serious relevant adverse pregnancy outcome that could be attributed to RTX exposure before and during early pregnancy in women with pemphigus was detected. Nevertheless, RTX should not be administered within 1 year before planned pregnancy, as not enough data is available yet. © 2022 Elsevier Inc. All rights reserved.

Related Docs

View other Related Docs

1. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)

2. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)

3. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)

4. A Comprehensive Review of Rituximab Therapy in Rheumatoid Arthritis Patients, Clinical Rheumatology (2019)

5. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)

6. Management of Pemphigus Disease in Pregnancy, American Journal of Reproductive Immunology (2017)

7. Pemphigus Disease and Area Index: Unmet Needs in the Real-World Management of Pemphigus, Oral Diseases (2023)

8. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (15)

Hamid Reza Mahmoodi (15)

Style	Citing Format
MLA	Dehghanimahmoudabadi A, et al.. "Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy." International Journal of Women's Dermatology, vol. 8, no. 3, 2022, pp. -.
APA	Dehghanimahmoudabadi A, Kianfar N, Akhdar M, Dasdar S, Balighi K, Mahmoudi H, Daneshpazhooh M (2022). Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy. International Journal of Women's Dermatology, 8(3), -.
Chicago	Dehghanimahmoudabadi A, Kianfar N, Akhdar M, Dasdar S, Balighi K, Mahmoudi H, Daneshpazhooh M. "Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy." International Journal of Women's Dermatology 8, no. 3 (2022): -.
Harvard	Dehghanimahmoudabadi A et al. (2022) 'Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy', International Journal of Women's Dermatology, 8(3), pp. -.
Vancouver	Dehghanimahmoudabadi A, Kianfar N, Akhdar M, Dasdar S, Balighi K, Mahmoudi H, et al.. Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy. International Journal of Women's Dermatology. 2022;8(3):-.
BibTex	@article{ author = {Dehghanimahmoudabadi A and Kianfar N and Akhdar M and Dasdar S and Balighi K and Mahmoudi H and Daneshpazhooh M}, title = {Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy}, journal = {International Journal of Women's Dermatology}, volume = {8}, number = {3}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Dehghanimahmoudabadi A AU - Kianfar N AU - Akhdar M AU - Dasdar S AU - Balighi K AU - Mahmoudi H AU - Daneshpazhooh M TI - Pregnancy Outcomes in Women With Pemphigus Exposed to Rituximab Before or During Pregnancy JO - International Journal of Women's Dermatology VL - 8 IS - 3 SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract